Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00054535 |
Recruitment Status :
Completed
First Posted : February 6, 2003
Last Update Posted : June 19, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Melanoma (Skin) | Biological: aldesleukin Biological: recombinant fowlpox-tyrosinase vaccine Biological: vaccinia-tyrosinase vaccine | Phase 2 |
OBJECTIVES:
- Determine the response rate (partial response or complete remission) in patients with metastatic melanoma treated with vaccinia-tyrosinase vaccine, fowlpox-tyrosinase vaccine, and high-dose interleukin-2.
- Determine the immunologic response, measured by the reactivity of CD4+ and CD8+ T cells and serum immunoglobulins against tyrosinase and melanoma cells, in patients treated with this regimen.
OUTLINE: Patients receive vaccinia-tyrosinase vaccine intramuscularly (IM) on day 1 followed by fowlpox-tyrosinase vaccine IM on days 15 and 29. Patients then receive high-dose interleukin-2 (IL-2) IV over 15 minutes every 8 hours beginning on day 30 for up to 12 doses and again beginning approximately 3 weeks after the initial dose. Patients with stable disease or a minor, mixed, or partial response may receive additional courses of fowlpox-tyrosinase vaccine (2 doses) and IL-2 as above in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 1 additional course beyond achieving CR.
Patients are followed annually for at least 5 years.
PROJECTED ACCRUAL: A total of 19-35 patients will be accrued for this study within 2 years.
Study Type : | Interventional (Clinical Trial) |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 |
Study Start Date : | January 2003 |
Actual Study Completion Date : | September 2004 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Diagnosis of metastatic melanoma
- Measurable disease
- Disease progression while receiving prior standard treatment
- No ocular or mucosal primary site
- No uncontrolled brain metastases
PATIENT CHARACTERISTICS:
Age
- 16 and over
Performance status
- ECOG 0-1
Life expectancy
- More than 3 months
Hematopoietic
- WBC at least 3,000/mm^3
- Platelet count at least 90,000/mm^3
- No coagulation disorders
Hepatic
- Bilirubin no greater than 1.6 mg/dL (less than 3.0 mg/dL in patients with Gilbert's syndrome)
- AST/ALT less than 3 times normal
- Hepatitis B surface antigen negative
- Hepatitis C antibody negative
Renal
- Creatinine no greater than 1.6 mg/dL
Cardiovascular
- No major cardiovascular illness
Pulmonary
- No major respiratory illness
Immunologic
- HIV negative
- No autoimmune disease
- No active systemic infections
- No primary or secondary immunodeficiency (e.g., hereditary disorders such as ataxia-telangiectasia or Wiskott-Aldrich syndrome or acquired immunodeficiencies after bone marrow transplantation)
- No allergy to eggs
- No prior allergy or untoward reaction to smallpox vaccination (if previously vaccinated)
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
-
No close contact with the following individuals for 2 weeks after vaccinia vaccination:
- Children under 5 years of age
- Pregnant women
- Individuals with prior or active eczema or other eczematoid skin disorders
- Individuals with other acute, chronic, or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
- Immunosuppressed individuals
- No active atopic dermatitis
- No prior or active eczema
-
No active cases of the following conditions:
- Extensive psoriasis
- Severe acneiform rash
- Impetigo
- Varicella zoster
- Burns
- Traumatic or pruritic skin conditions
- Open wounds
-
No unhealed surgical scars
- Healed surgical stomas (e.g., colostomy) allowed
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior recombinant vaccinia or fowlpox vaccines for melanoma
-
No prior vaccination with full length tyrosinase protein, or a vector encoding the full length protein for melanoma
- Prior individual tyrosinase peptides are allowed
- No prior high-dose interleukin-2
Chemotherapy
- Not specified
Endocrine therapy
- No concurrent oral, IV, topical, or inhaled steroids
Radiotherapy
- Not specified
Surgery
- Recovered from prior surgery
Other
- Recovered from prior therapy for melanoma
- More than 3 weeks since prior systemic therapy for melanoma
- No other concurrent systemic therapy for melanoma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00054535
United States, Maryland | |
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |
Bethesda, Maryland, United States, 20892-1182 |
Study Chair: | Suzanne L. Topalian, MD | NCI - Surgery Branch |
ClinicalTrials.gov Identifier: | NCT00054535 |
Obsolete Identifiers: | NCT00051610 |
Other Study ID Numbers: |
CDR0000270794 NCI-03-C-0080 NCI-6119 |
First Posted: | February 6, 2003 Key Record Dates |
Last Update Posted: | June 19, 2013 |
Last Verified: | July 2004 |
stage IV melanoma recurrent melanoma |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms by Site |
Skin Diseases Aldesleukin Vaccines Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |